Craft

Shenzhen Salubris Pharmaceutical

Stock Price

¥33

2024-10-29

Market Capitalization

¥35.8 B

2024-10-29

Revenue

¥4.2 B

FY, 2025

Shenzhen Salubris Pharmaceutical Summary

Company Summary

Overview
Shenzhen Salubris Pharmaceutical (深圳信立泰药业股份有限公司) is a pharmaceutical company that develops and supplies drugs. It offers tablets, capsules, injections, and active pharmaceutical ingredients products for depression, epileptics and allergy, infection, osteoporosis, etc. The company also focuses on chronic diseases such as cardiovascular and cerebrovascular diseases.
Type
Public
Status
Active
Founded
1998
HQ
Shenzhen, CN | view all locations
Website
https://www.salubris.com/
Cybersecurity rating
Sectors

Key People

  • Samuel Murphy

    Samuel Murphy, VP and Head of International Business Development

    • Heng Xie

    LocationsView all

    1 location detected

    • Shenzhen, Guang Dong Sheng HQ

      China

      37F, Tower B, NEO Building No. 6009 Shennan Road

    Shenzhen Salubris Pharmaceutical Financials

    Summary Financials

    Revenue (Q1, 2026)
    ¥1.2B
    Gross profit (Q1, 2026)
    ¥923.2M
    Net income (Q1, 2026)
    ¥225.8M
    Cash (Q1, 2026)
    ¥1.1B
    EBIT (Q1, 2026)
    ¥248.9M
    Enterprise value
    $35.4B

    Footer menu